A citation-based method for searching scientific literature

Andreia Neves-Carvalho, Sara Duarte-Silva, Andreia Teixeira-Castro, Patrícia Maciel. Expert Opin Ther Targets 2020
Times Cited: 3







List of co-cited articles
27 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical Features of Machado-Joseph Disease.
Nuno Mendonça, Marcondes C França, António Freire Gonçalves, Cristina Januário. Adv Exp Med Biol 2018
7
66

Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
Philipp Koch, Peter Breuer, Michael Peitz, Johannes Jungverdorben, Jaideep Kesavan, Daniel Poppe, Jonas Doerr, Julia Ladewig, Jerome Mertens, Thomas Tüting,[...]. Nature 2011
226
66

Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.
Andreia Teixeira-Castro, Ana Jalles, Sofia Esteves, Soosung Kang, Liliana da Silva Santos, Anabela Silva-Fernandes, Mário F Neto, Renée M Brielmann, Carlos Bessa, Sara Duarte-Silva,[...]. Brain 2015
50
66

Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.
Anabela Silva-Fernandes, Sara Duarte-Silva, Andreia Neves-Carvalho, Marina Amorim, Carina Soares-Cunha, Pedro Oliveira, Kenneth Thirstrup, Andreia Teixeira-Castro, Patrícia Maciel. Neurotherapeutics 2014
67
66

From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Jorge Diogo Da Silva, Andreia Teixeira-Castro, Patrícia Maciel. Neurotherapeutics 2019
16
66

Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.
Maria do Carmo Costa, Naila S Ashraf, Svetlana Fischer, Yemen Yang, Emily Schapka, Gnanada Joshi, Thomas J McQuade, Rahil M Dharia, Mark Dulchavsky, Michelle Ouyang,[...]. Brain 2016
25
66

Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias.
Antoni Matilla-Dueñas, Ivelisse Sánchez, Marc Corral-Juan, Antoni Dávalos, Ramiro Alvarez, Pilar Latorre. Cerebellum 2010
62
66

Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.
Pavitra S Ramachandran, Ryan L Boudreau, Kellie A Schaefer, Albert R La Spada, Beverly L Davidson. Mol Ther 2014
37
66

An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron.
Yu Miyazaki, Xiaofei Du, Shin-Ichi Muramatsu, Christopher M Gomez. Sci Transl Med 2016
36
66

Targeting potassium channels to treat cerebellar ataxia.
David D Bushart, Ravi Chopra, Vikrant Singh, Geoffrey G Murphy, Heike Wulff, Vikram G Shakkottai. Ann Clin Transl Neurol 2018
30
66


Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.
Daniel R Scoles, Pratap Meera, Matthew D Schneider, Sharan Paul, Warunee Dansithong, Karla P Figueroa, Gene Hung, Frank Rigo, C Frank Bennett, Thomas S Otis,[...]. Nature 2017
150
66

Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease.
Maria do Carmo Costa, Katiuska Luna-Cancalon, Svetlana Fischer, Naila S Ashraf, Michelle Ouyang, Rahil M Dharia, Lucas Martin-Fishman, Yemen Yang, Vikram G Shakkottai, Beverly L Davidson,[...]. Mol Ther 2013
70
66

Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7.
Chenchen Niu, Thazah P Prakash, Aneeza Kim, John L Quach, Laryssa A Huryn, Yuechen Yang, Edith Lopez, Ali Jazayeri, Gene Hung, Bryce L Sopher,[...]. Sci Transl Med 2018
38
66

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion.
Anna Niewiadomska-Cimicka, Antoine Hache, Yvon Trottier. Front Neurosci 2020
6
66

Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.
Megan S Keiser, Jeffrey H Kordower, Pedro Gonzalez-Alegre, Beverly L Davidson. Brain 2015
25
66

CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Shuming Ouyang, Yingjun Xie, Zeyu Xiong, Yi Yang, Yexing Xian, Zhanhui Ou, Bing Song, Yuchang Chen, Yuhuan Xie, Haoxian Li,[...]. Stem Cells Dev 2018
29
66

Pathogenesis of SCA3 and implications for other polyglutamine diseases.
Hayley S McLoughlin, Lauren R Moore, Henry L Paulson. Neurobiol Dis 2020
34
66

The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies.
Luis Ruano, Claudia Melo, M Carolina Silva, Paula Coutinho. Neuroepidemiology 2014
263
66

RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.
Haibin Xia, Qinwen Mao, Steven L Eliason, Scott Q Harper, Inês H Martins, Harry T Orr, Henry L Paulson, Linda Yang, Robert M Kotin, Beverly L Davidson. Nat Med 2004
488
66

Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model.
Kei Watase, Jennifer R Gatchel, Yaling Sun, Effat Emamian, Richard Atkinson, Ronald Richman, Hidehiro Mizusawa, Harry T Orr, Chad Shaw, Huda Y Zoghbi. PLoS Med 2007
112
66

Spinocerebellar ataxias: prospects and challenges for therapy development.
Tetsuo Ashizawa, Gülin Öz, Henry L Paulson. Nat Rev Neurol 2018
80
66

Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.
A Matilla-Dueñas, T Ashizawa, A Brice, S Magri, K N McFarland, M Pandolfo, S M Pulst, O Riess, D C Rubinsztein, J Schmidt,[...]. Cerebellum 2014
79
66

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
Hayley S McLoughlin, Lauren R Moore, Ravi Chopra, Robert Komlo, Megan McKenzie, Kate G Blumenstein, Hien Zhao, Holly B Kordasiewicz, Vikram G Shakkottai, Henry L Paulson. Ann Neurol 2018
67
66

Spinocerebellar ataxia: an update.
Roisin Sullivan, Wai Yan Yau, Emer O'Connor, Henry Houlden. J Neurol 2019
59
66

Cellular and circuit mechanisms underlying spinocerebellar ataxias.
Pratap Meera, Stefan M Pulst, Thomas S Otis. J Physiol 2016
34
66

A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.
T A Zesiewicz, P E Greenstein, K L Sullivan, L Wecker, A Miller, I Jahan, R Chen, S L Perlman. Neurology 2012
68
66

The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.
R Depoortere, T H Johnston, S H Fox, J M Brotchie, A Newman-Tancredi. Parkinsonism Relat Disord 2020
3
33

Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists.
Stefan Bollinger, Harald Hübner, Frank W Heinemann, Karsten Meyer, Peter Gmeiner. J Med Chem 2010
14
33

Receptors and other signaling proteins required for serotonin control of locomotion in Caenorhabditis elegans.
Güliz Gürel, Megan A Gustafson, Judy S Pepper, H Robert Horvitz, Michael R Koelle. Genetics 2012
45
33

Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia.
F C Colpaert, J P Tarayre, W Koek, P J Pauwels, L Bardin, X-J Xu, Z Wiesenfeld-Hallin, C Cosi, E Carilla-Durand, M B Assié,[...]. Neuropharmacology 2002
100
33

Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse.
A M Laporte, L Lima, H Gozlan, M Hamon. Eur J Pharmacol 1994
80
33



Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease.
Joana Duarte-Neves, Nélio Gonçalves, Janete Cunha-Santos, Ana Teresa Simões, Wilfred F A den Dunnen, Hirokazu Hirai, Sebastian Kügler, Cláudia Cavadas, Luís Pereira de Almeida. Hum Mol Genet 2015
36
33




18F-F13640 PET imaging of functional receptors in humans.
Matthieu Colom, Nicolas Costes, Jérôme Redouté, Frédéric Dailler, Florent Gobert, Didier Le Bars, Thierry Billard, Adrian Newman-Tancredi, Luc Zimmer. Eur J Nucl Med Mol Imaging 2020
12
33

Pharmacological principles of antidepressant efficacy.
Alan F Schatzberg. Hum Psychopharmacol 2002
25
33

Treatment of cerebellar ataxia with 5-HT1A agonist.
Asako Takei, Takeshi Hamada, Ichiro Yabe, Hidenao Sasaki. Cerebellum 2005
19
33

Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.
Maria J Ramirez, Mitchell K P Lai, Rosa M Tordera, Paul T Francis. Drugs 2014
53
33

Protein aggregation and neurodegenerative disease.
Christopher A Ross, Michelle A Poirier. Nat Med 2004
33

A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease.
Krista L Lanctôt, Doug F Hussey, Nathan Herrmann, Sandra E Black, Pablo M Rusjan, Alan A Wilson, Sylvain Houle, Nicole Kozloff, Nicholaas Paul L G Verhoeff, Shitij Kapur. Am J Geriatr Psychiatry 2007
40
33


Use of buspirone for treatment of cerebellar ataxia. An open-label study.
J S Lou, L Goldfarb, L McShane, P Gatev, M Hallett. Arch Neurol 1995
66
33



Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease.
Naila S Ashraf, Sara Duarte-Silva, Emily D Shaw, Patrícia Maciel, Henry L Paulson, Andreia Teixeira-Castro, Maria do Carmo Costa. Mol Neurobiol 2019
9
33

Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
Hassan Mellatyar, Sona Talaei, Younes Pilehvar-Soltanahmadi, Abolfazl Barzegar, Abolfazl Akbarzadeh, Arman Shahabi, Mazyar Barekati-Mowahed, Nosratollah Zarghami. Biomed Pharmacother 2018
41
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.